United States Patent 5,707,980: Claim Scope, Exclusivity History, and Vitamin D Analog Patent Landscape

U.S. Patent No. 5,707,980 covers methods of treating secondary hyperparathyroidism associated with end-stage renal disease by administering 1α,25-dihydroxyvitamin D4, alone or with bone-preserving agents. Its core protection is a treatment method, not a composition-of-matter claim. The patent does not cover all vitamin D analogs, all hyperparathyroidism treatments, or all uses of doxercalciferol-related compounds.

The patent issued on January 13, 1998. Based on the standard 20-year patent term measured from the earliest effective nonprovisional filing date, its enforceable term has expired. The claims therefore have no current blocking effect in the United States, although they remain relevant to historical freedom-to-operate analyses, patent-family mapping, validity review, and the development of later vitamin D analog products. [1]

What drug and therapeutic use does U.S. Patent 5,707,980 cover?

The patent covers the use of 1α,25-dihydroxyvitamin D4 to reduce or maintain reduced serum parathyroid hormone in human patients with secondary hyperparathyroidism caused by end-stage renal disease.

The central claim elements are:

Claim element	Requirement
Patient	Human patient
Disease setting	Hyperparathyroidism secondary to end-stage renal disease
Active agent	1α,25-dihydroxyvitamin D4 for claims 1-9
Therapeutic outcome	Lowering or maintaining lowered serum parathyroid hormone
Administration	Oral, parenteral, or other specified routes
Dose	1 to approximately 100 μg per week under claim 2
Combination therapy	Permitted under claims 6, 7, 10, and 11
Claim category	Method of treatment

The patent is directed to the use of a vitamin D4 analog as a parathyroid hormone-lowering therapy. It does not claim a pharmaceutical composition in the conventional composition-of-matter sense, nor does it claim the chemical compound itself.

What does claim 1 of U.S. Patent 5,707,980 require?

Claim 1 requires all of the following:

A human patient.
Secondary hyperparathyroidism.
The secondary hyperparathyroidism must be associated with end-stage renal disease.
Administration of an effective amount of 1α,25-dihydroxyvitamin D4.
The purpose or result must be lowering and maintaining lowered serum parathyroid hormone levels.

This is a narrow disease-and-patient-population claim. A product or treatment that uses the same analog for primary hyperparathyroidism, tertiary hyperparathyroidism, osteoporosis, vitamin D deficiency, or another indication would not literally satisfy the disease limitation in claim 1.

The claim also contains a functional treatment limitation. The administered amount must be effective to lower or maintain lowered serum parathyroid hormone. Mere administration of the compound, without the claimed therapeutic purpose or effect, would not necessarily meet the claim.

How broad is the term “vitamin D analog” in the patent?

Claims 1 through 9 use the phrase “a vitamin D analog” but expressly identify that analog as 1α,25-dihydroxyvitamin D4. The species limitation controls the scope.

A competing vitamin D analog such as paricalcitol, calcitriol, alfacalcidol, or doxercalciferol would not literally fall within claims 1 through 9 solely because it is also a vitamin D analog. Each has a different chemical structure:

Compound	Common description	Relationship to the claimed compound
1α,25-dihydroxyvitamin D4	Claimed D4 analog	Expressly identified in claims 1-9
Calcitriol	1α,25-dihydroxyvitamin D3	Different side-chain structure
Doxercalciferol	1α-hydroxyvitamin D2	Different hydroxylation state and vitamin D series
Paricalcitol	19-nor vitamin D analog	Structurally modified D3 analog
Alfacalcidol	1α-hydroxyvitamin D3	Prodrug-type vitamin D analog
Ergocalciferol	Vitamin D2	Not the claimed active compound

A broader genus appears in claim 10. That claim covers an analog defined by a structural formula and limitations concerning the C-22/C-23 bond and the R1 substituent. The claim also requires combination treatment with an agent that reduces bone loss or loss of bone mineral content.

Claim 10 is therefore broader in chemical format than claim 1, but narrower in treatment design because it requires combination therapy.

What administration routes are protected?

The patent claims multiple administration routes, but the scope differs by claim.

Oral administration

Claim 3 covers the analog in solution, in a liquid vehicle that is ingestible and nontoxic, administered orally in encapsulated form.

Claim 9 separately covers oral administration of 1α,25-(OH)2-vitamin D4 in an amount sufficient to lower serum parathyroid hormone. Claim 9 is important because it does not require the specific solution-in-liquid-vehicle-and-capsule formulation stated in claim 3.

The oral claims may therefore reach:

Encapsulated liquid formulations;
Oral administration of the compound where the formulation is not limited to the specific vehicle language in claim 3;
Treatment regimens that measure or evaluate serum parathyroid hormone over time.

Parenteral administration

Claim 4 covers parenteral administration. Claim 5 provides examples:

Subcutaneous injection;
Intramuscular injection;
Intravenous injection;
Nasopharyngeal or mucosal absorption;
Transdermal absorption.

The use of “comprising” in the claims generally leaves room for additional treatment steps, excipients, dosing adjustments, monitoring, or co-administered agents.

Nonparenteral administration

Claim 8 covers nonparenteral administration. This is a broad route category that may include oral and other noninvasive delivery routes, subject to the limitations inherited from claim 1.

The claims should not be read as granting a separate monopoly over every possible delivery system. Each route remains tied to the specified compound, patient population, disease condition, and parathyroid hormone-lowering purpose.

What dosage range does the patent protect?

Claim 2 specifies a dosage of 1 to about 100 micrograms per week.

This dependent claim narrows claim 1 by adding a quantitative dosing limitation. It does not necessarily require a fixed dose administered once weekly. Depending on claim construction and the patent disclosure, a weekly total could potentially be delivered through divided doses, but the claim language itself does not expressly define dosing frequency beyond the stated weekly amount.

The range has several practical boundaries:

Below 1 μg per week would fall outside the literal range of claim 2, although it could remain relevant to claim 1 if therapeutically effective.
Above approximately 100 μg per week would fall outside claim 2, but could remain within claim 1.
A dose within the range would not infringe claim 2 unless the other limitations of claim 1 were also satisfied.

The dose claim is therefore narrower than the core method claim and likely more vulnerable to design-around through a different total weekly dose, assuming the alternative remains clinically acceptable.

What combination therapies are protected?

Claims 6, 7, 10, and 11 address combination treatment.

Claim 6 covers administration with at least one agent capable of reducing loss of bone mass or bone mineral content. Claim 7 lists examples:

Other vitamin D compounds;
Conjugated estrogens;
Sodium fluorides;
Bisphosphonates;
Cobalamin;
Pertussis toxin;
Boron.

Claims 10 and 11 apply a similar combination requirement to the structural genus in claim 10.

The combination claims require more than the simultaneous presence of two substances in a patient. The other agent must be characterized by the claimed bone-preserving capability. The combination must also remain within the underlying hyperparathyroidism and vitamin D analog limitations.

The inclusion of pertussis toxin and boron indicates that the patent disclosure contemplated a broad bone-metabolism treatment platform rather than a narrow commercial formulation. Those listed agents do not, by themselves, create an independent patent right. The claims require their use with the covered vitamin D analog treatment.

What is the difference between claims 1 and 9?

Claims 1 and 9 overlap but are not identical.

Issue	Claim 1	Claim 9
Compound	1α,25-dihydroxyvitamin D4	1α,25-(OH)2-vitamin D4
Patient	Human patients	Human in need of treatment
Disease	Secondary hyperparathyroidism from ESRD	Pathological effects of the same condition
Route	Not limited in the independent claim	Oral administration required
Result	Lowering or maintaining lowered serum PTH	Lowering serum PTH measured over time
Treatment objective	Serum PTH control	Alleviation or prevention of pathological effects

Claim 9 may be read as an oral-treatment claim with a more explicit measurement and outcome limitation. It also frames the treatment as alleviating or preventing pathological effects, which may create a distinct infringement and validity analysis from claim 1.

What does claim 10 add to the patent?

Claim 10 introduces a structural formula for the vitamin D analog and adds mandatory combination therapy.

The principal limitations are:

A defined vitamin D analog structure;
A choice involving the C-22/C-23 bond;
R1 as hydrogen or hydroxyl, subject to the stated proviso;
Treatment of secondary hyperparathyroidism in end-stage renal disease;
Lowering or maintaining lowered serum parathyroid hormone;
Combination with an agent that reduces bone mass or bone mineral loss.

Claim 10 is not simply a broader version of claim 1. It expands the chemical definition but narrows the therapeutic regimen by requiring a bone-preserving combination agent.

A product using the claimed structure without the required combination agent would face a different analysis under claim 10 than under claims 1 through 9.

When did U.S. Patent 5,707,980 lose exclusivity?

The patent issued in 1998 and has expired under the ordinary U.S. patent-term framework. The relevant statutory framework generally provides a term of 20 years from the earliest effective nonprovisional filing date for applications filed after June 8, 1995. [2]

The patent cannot now support a new U.S. patent infringement action for conduct occurring after expiration. Patent expiration does not erase the historical claims or eliminate their relevance to:

Patent-family analysis;
Historical generic challenges;
Due-diligence reviews;
Invalidity research;
Continuation and divisional tracking;
Patent-term-adjustment calculations;
International counterpart reviews.

Any exact terminal-disclaimer or patent-term-adjustment issue must be confirmed against the USPTO Patent Center record and the face of the patent. The issued patent itself is the controlling source for the expiration calculation. [1]

What was the FDA and Orange Book status?

U.S. Patent 5,707,980 is a method-of-treatment patent. Orange Book listing depends on whether the patent was submitted for an approved drug and whether it met FDA listing requirements at the relevant time.

The patent is associated with the vitamin D analog treatment field, including doxercalciferol-related renal hyperparathyroidism products. Doxercalciferol, marketed as Hectorol, is 1α-hydroxyvitamin D2 and is chemically distinct from 1α,25-dihydroxyvitamin D4. The existence of an approval for doxercalciferol does not establish that Patent 5,707,980 claims doxercalciferol. [3]

The FDA Orange Book should be analyzed separately from the patent document:

Regulatory question	Relevance
Is the patent listed against an approved product?	Determines whether an ANDA applicant must address it
Is the patent expired?	Determines whether it creates a current regulatory delay
Is the patent a method-of-use patent?	May permit a section viii label carve-out
Is the claimed use approved and listed?	Determines practical Hatch-Waxman significance
Is the product a small-molecule drug?	Determines ANDA, not biosimilar, pathway relevance

Because the patent has expired, it does not currently impose a 30-month stay or other active Orange Book-based launch barrier. Paragraph IV disputes would have historical rather than current blocking significance. [4]

Were Paragraph IV challenges likely relevant?

For an unexpired listed method-of-use patent, an ANDA applicant could have used:

A Paragraph IV certification alleging invalidity or noninfringement; or
A section viii statement seeking approval without the patented method, where FDA listing and labeling rules permitted the carve-out.

The practical value of a Paragraph IV challenge would have depended on whether the ANDA proposed the same disease indication and dosing instructions covered by the patent. A generic applicant targeting renal secondary hyperparathyroidism would have faced greater exposure than one seeking approval for a noncovered use.

After expiration, the Paragraph IV issue becomes largely historical. A generic applicant no longer needs to defeat an expired patent to enter the market, although separate unexpired patents, regulatory exclusivity, labeling restrictions, or product-specific patents could remain relevant.

Are biosimilar risks relevant to this patent?

No. Patent 5,707,980 concerns a chemically defined small-molecule vitamin D analog and claims methods of administering it. It is not a biologic patent and does not create a biosimilar pathway issue under the Biologics Price Competition and Innovation Act.

Competitive entry would proceed through generic-drug pathways, principally an abbreviated new drug application, rather than a 351(k) biosimilar application. [5]

The relevant competitive risks are:

Generic substitution;
Formulation differentiation;
Alternative vitamin D analogs;
Label carve-outs;
Noninfringing dosing regimens;
Competing renal hyperparathyroidism therapies.

What formulation patents and manufacturing barriers should be reviewed?

Patent 5,707,980 provides limited formulation protection. Claim 3 covers a particular oral presentation involving the analog in solution, a liquid vehicle, and encapsulated administration. It does not claim every capsule, tablet, injectable, liquid, or transdermal formulation.

A complete product patent landscape should separate:

Compound patents;
Salt, solvate, and polymorph patents;
Oral formulation patents;
Injectable formulation patents;
Stability and packaging patents;
Manufacturing and purification patents;
Treatment-regimen patents;
Combination-treatment patents;
Use patents for dialysis or chronic kidney disease populations.

Manufacturing barriers may be more important than this patent. Vitamin D analog production can require stereochemical control, protection and deprotection steps, side-chain construction, impurity control, and sensitive analytical methods. Those technical barriers may affect commercial entry even when the principal treatment patent has expired.

Patent 5,707,980 itself does not claim a manufacturing method. It therefore does not directly prevent synthesis of the compound using a different process.

How strong was the patent estate?

The estate was commercially meaningful but legally narrow.

Strengths

It targeted a defined and clinically important patient population.
It claimed a specific serum parathyroid hormone-lowering use.
It covered oral and parenteral treatment routes.
It included a dose-range dependent claim.
It included combination therapy with bone-preserving agents.
It contained both a species-focused claim set and a structural genus claim.

Limitations

The core claims are method claims rather than composition claims.
The compound is limited to 1α,25-dihydroxyvitamin D4 in the principal species claims.
Claims 6, 7, 10, and 11 require combination therapy.
Competitors could potentially use structurally different vitamin D analogs.
Competitors could target different indications or omit the claimed ESRD population.
The patent has expired.

For historical enforcement, the strongest claims would likely have been claims 1 and 9 because they directly address the principal treatment concept. Claim 2 adds a potentially useful dosage limitation but creates a narrower target. Claims 3 through 8 are route and formulation claims. Claims 10 and 11 extend the chemical scope but require combination treatment.

How does Patent 5,707,980 compare with competing vitamin D analog estates?

Product or compound	Primary clinical use	Patent 5,707,980 relationship	Main patent risk category
1α,25-dihydroxyvitamin D4	Claimed ESRD secondary hyperparathyroidism use	Directly covered by species claims	Historical expired method claims
Calcitriol	Secondary hyperparathyroidism and vitamin D disorders	Different D3 compound	Separate compound, formulation, and use patents
Doxercalciferol	Secondary hyperparathyroidism in chronic kidney disease	Different D2 compound	Product-specific formulation and use patents
Paricalcitol	Secondary hyperparathyroidism in chronic kidney disease	Different 19-nor analog	Separate composition and method estate
Cinacalcet	Calcimimetic treatment for hyperparathyroidism	Mechanistically different	Separate compound, formulation, and indication patents
Etelcalcetide	Injectable calcimimetic	Peptide drug, not vitamin D analog	Biologic-like peptide and manufacturing issues

The commercial landscape therefore cannot be assessed by Patent 5,707,980 alone. The patent is one historical layer in a broader renal hyperparathyroidism field that includes vitamin D receptor agonists and calcimimetics.

What litigation and settlement issues affect the patent?

The patent’s expiration eliminates current infringement exposure under the patent. Any historic litigation or settlement would matter mainly for:

Launch-date analysis;
Damages periods;
At-risk launch assessment;
Authorized-generic arrangements;
Exclusivity calculations;
Patent-family diligence.

A definitive litigation history must be tied to docket records, PACER, the USPTO assignment database, and FDA Orange Book certifications. The patent text alone does not establish whether a particular ANDA applicant made a Paragraph IV certification, whether litigation was filed, or whether a settlement agreement existed.

What generic launch scenarios exist now?

The patent itself does not prevent current generic launch because it has expired. Current launch risk depends on other barriers:

Whether the proposed generic contains the same active ingredient as an approved reference product.
Whether FDA has an approved reference listed drug for the relevant compound.
Whether unexpired product, formulation, or method patents remain.
Whether the proposed labeling includes the ESRD secondary hyperparathyroidism indication.
Whether the product can demonstrate bioequivalence.
Whether manufacturing controls meet FDA requirements.
Whether a separate exclusivity period remains attached to the reference product.

For a product containing 1α,25-dihydroxyvitamin D4, the commercial issue may be regulatory and manufacturing feasibility rather than infringement of Patent 5,707,980.

Key Takeaways

U.S. Patent 5,707,980 claims treatment methods using 1α,25-dihydroxyvitamin D4.
The principal indication is secondary hyperparathyroidism associated with end-stage renal disease.
Claim 1 is the central species-focused method claim.
Claim 2 covers a 1 to approximately 100 μg/week dosage range.
Claims 3 through 5 address oral, parenteral, injectable, mucosal, and transdermal delivery.
Claims 6, 7, 10, and 11 cover combination therapy with bone-preserving agents.
Claim 10 introduces a structural genus but requires combination treatment.
The patent does not claim doxercalciferol, paricalcitol, calcitriol, or all vitamin D analogs.
It is not a biologic patent and does not create biosimilar risk.
Its U.S. patent term has expired, eliminating current blocking effect.
Any present-day market barrier must arise from later patents, FDA exclusivity, manufacturing constraints, or regulatory requirements.

FAQs

Does U.S. Patent 5,707,980 claim doxercalciferol?

No. Doxercalciferol is 1α-hydroxyvitamin D2. The principal claims identify 1α,25-dihydroxyvitamin D4, which is a different compound.

Can a generic use calcitriol without infringing Patent 5,707,980?

The claims supplied do not literally cover calcitriol because calcitriol is 1α,25-dihydroxyvitamin D3, not the claimed D4 analog. Separate patents and regulatory requirements must be reviewed.

Does the patent cover treating primary hyperparathyroidism?

No. The principal claims require hyperparathyroidism secondary to end-stage renal disease. Primary hyperparathyroidism is outside that express limitation.

Does the patent protect a capsule as a product?

No. Claim 3 is a method claim involving oral administration of the analog in solution, in an ingestible liquid vehicle, in encapsulated form. It is not a standalone composition claim.

Can the expired patent still support an FDA Paragraph IV challenge?

No current challenge is necessary against an expired patent. Paragraph IV certifications address listed patents that could otherwise delay approval. An expired patent does not create a current patent-based market-entry block.

References

U.S. Patent No. 5,707,980, “Methods for lowering serum parathyroid hormone using vitamin D analogs,” issued Jan. 13, 1998, United States Patent and Trademark Office.
35 U.S.C. § 154(a), patent term provisions, United States Code.
U.S. Food and Drug Administration. (n.d.). Hectorol (doxercalciferol) prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application pathway and generic drug approvals. FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	247817	⤷ Start Trial
Austria	114471	⤷ Start Trial
Austria	250566	⤷ Start Trial
Austria	258796	⤷ Start Trial
Austria	347366	⤷ Start Trial
Australia	2002322346	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,707,980

Summary for Patent: 5,707,980